A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
Public ClinicalTrials.gov record NCT03278028. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
Study identification
- NCT ID
- NCT03278028
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 8 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 12, 2017
- Primary completion
- Feb 28, 2018
- Completion
- Feb 28, 2018
- Last update posted
- Apr 8, 2019
2017 – 2018
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Aclaris Investigational Site | Glendale | Arizona | 85308 | — |
| Aclaris Investigational Site | Fort Smith | Arkansas | 72916 | — |
| Aclaris Investigational Site | Encinitas | California | 92024 | — |
| Aclaris Investigational Site | Los Angeles | California | 90045 | — |
| Aclaris Investigational Site | Denver | Colorado | 80210 | — |
| Aclaris Investigational Site | Omaha | Nebraska | 68144 | — |
| Aclaris Investigational Site | Albuquerque | New Mexico | 87106 | — |
| Aclaris Investigational Site | Rochester | New York | 14623 | — |
| Aclaris Investigational Site | High Point | South Carolina | 27262 | — |
| Aclaris Investigational Site | Knoxville | Tennessee | 37922 | — |
| Aclaris Investigational Site | Nashville | Tennessee | 37215 | — |
| Aclaris Investigational Site | College Station | Texas | 77845 | — |
| Aclaris Investigational Site | Houston | Texas | 77004 | — |
| Aclaris Investigational Site | Salt Lake City | Utah | 84117 | — |
| Aclaris Investigational Site | Lynchburg | Virginia | 24501 | — |
| Aclaris Investigational Site | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03278028, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2019 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03278028 live on ClinicalTrials.gov.